Skip to main content
Journal cover image

Promise of factor Xa inhibition in atrial fibrillation.

Publication ,  Journal Article
Al-Khatib, SM; Alexander, JH; Lopes, RD; Mahaffey, KW; Patel, MR; Granger, CB
Published in: Curr Cardiol Rep
February 2012

Randomized clinical trials have conclusively demonstrated that warfarin prevents stroke in patients with atrial fibrillation. This evidence led the American College of Cardiology, the American Heart Association, and the European Society of Cardiology to designate warfarin as a Class I indication in patients at moderate to high risk for stroke. Despite the evidence from randomized clinical trials and clear practice guidelines, warfarin is underutilized in many eligible patients. This is, at least in part, due to the many challenges associated with warfarin use that have led to the development of many new anticoagulants including direct thrombin inhibitors and factor Xa inhibitors. In this article, we review the complexities of anticoagulation in patients with atrial fibrillation, underscoring the challenges related to warfarin use, and present an overview of new anticoagulants particularly, factor Xa inhibitors, with special emphasis on emerging data from randomized clinical trials on their efficacy and safety in the management of atrial fibrillation.

Duke Scholars

Published In

Curr Cardiol Rep

DOI

EISSN

1534-3170

Publication Date

February 2012

Volume

14

Issue

1

Start / End Page

70 / 78

Location

United States

Related Subject Headings

  • beta-Alanine
  • Warfarin
  • United States
  • Stroke
  • Risk Factors
  • Randomized Controlled Trials as Topic
  • Male
  • Humans
  • Female
  • Factor Xa Inhibitors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Al-Khatib, S. M., Alexander, J. H., Lopes, R. D., Mahaffey, K. W., Patel, M. R., & Granger, C. B. (2012). Promise of factor Xa inhibition in atrial fibrillation. Curr Cardiol Rep, 14(1), 70–78. https://doi.org/10.1007/s11886-011-0230-1
Al-Khatib, Sana M., John H. Alexander, Renato D. Lopes, Kenneth W. Mahaffey, Manesh R. Patel, and Christopher B. Granger. “Promise of factor Xa inhibition in atrial fibrillation.Curr Cardiol Rep 14, no. 1 (February 2012): 70–78. https://doi.org/10.1007/s11886-011-0230-1.
Al-Khatib SM, Alexander JH, Lopes RD, Mahaffey KW, Patel MR, Granger CB. Promise of factor Xa inhibition in atrial fibrillation. Curr Cardiol Rep. 2012 Feb;14(1):70–8.
Al-Khatib, Sana M., et al. “Promise of factor Xa inhibition in atrial fibrillation.Curr Cardiol Rep, vol. 14, no. 1, Feb. 2012, pp. 70–78. Pubmed, doi:10.1007/s11886-011-0230-1.
Al-Khatib SM, Alexander JH, Lopes RD, Mahaffey KW, Patel MR, Granger CB. Promise of factor Xa inhibition in atrial fibrillation. Curr Cardiol Rep. 2012 Feb;14(1):70–78.
Journal cover image

Published In

Curr Cardiol Rep

DOI

EISSN

1534-3170

Publication Date

February 2012

Volume

14

Issue

1

Start / End Page

70 / 78

Location

United States

Related Subject Headings

  • beta-Alanine
  • Warfarin
  • United States
  • Stroke
  • Risk Factors
  • Randomized Controlled Trials as Topic
  • Male
  • Humans
  • Female
  • Factor Xa Inhibitors